REGULATORY
MATTERS
|
• |
Aprotinin
|
• |
Asenapine
maleate |
• |
Ceftriaxone |
• |
Citalopram
hydrobromide |
• |
Clopidogrel
and proton-pump inhibitors |
• |
Dasatinib |
• |
Dronedarone |
• |
Finasteride |
• |
Fluconazole |
• |
Fusidic
acid and Statins |
• |
Gonadotropin-releasing
hormone agonists |
• |
Isotretinoin |
• |
Lenalidomide |
• |
Terpenic-based
anti-cough medicines |
• |
Tumour
Necrosis Factor-alpha Blockers |
• |
Zoledronic
acid
|
SAFETY
OF MEDICINE
|
• |
Bevacizumab
|
• |
Bisphosphonates |
• |
Drospirenone-containing
combined oral contraceptives |
• |
Gadolinium
based contrast agents |
• |
Ondansetron |
• |
Proton
pump inhibitors |
• |
Quinine |
• |
Uromitexan |
• |
Venlafaxine |
FEATURE
|
• |
FIP
pharmacovigilance seminar in India
|